Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI reads tumor slides to forecast cancer spread

NCT ID NCT07244094

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses artificial intelligence to analyze standard tissue samples from breast cancer patients. The goal is to predict which patients are at higher risk of the cancer spreading to other parts of the body. Researchers will train the AI on slides from 400 women who had surgery between 2015 and 2025. If successful, this tool could help doctors personalize follow-up care and treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study participants will be selected from a case-control cohort of adult female patients diagnosed with primary invasive breast cancer who underwent curative surgery at participating centers (e.g., The Second Affiliated Hospital of Zhejiang University) between January 2015 and December 2025. Eligible individuals must have available, high-quality archived primary tumor tissue samples, specifically H\&E-stained whole-slide images and consecutive sections for multiplex immunohistochemistry, coupled with complete clinicopathological data and long-term follow-up information documenting distant metastasis status. The final study sample will consist of patients from this source population who meet all predefined inclusion and exclusion criteria, ensuring data integrity and cohort homogeneity for AI model development.

Ages

18 to 95 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients aged 18 years or older. 2. Histologically confirmed primary invasive breast carcinoma. 3. Underwent curative surgical resection (mastectomy or breast-conserving surgery) between January 2015 and December 2025. 4. Before initiating the neoadjuvant therapy, there was a retention of the primary tumor specimen. 5. Availability of high-quality, digitizable Hematoxylin and Eosin (H\&E) stained whole-slide images (WSIs). 6. Availability of consecutive tissue sections from the same tumor block for multiplex immunohistochemistry (mIHC) staining (including markers such as Pan-CK, CD3, CD20). 7. Complete clinicopathological data and follow-up information must be available, including but not limited to: TNM stage, histological grade, molecular subtype (ER, PR, HER2 status), adjuvant treatment records, and clearly documented distant metastasis-free survival (DMFS) data. 8. A minimum follow-up of 5 years for patients with detailed information for distant metastasis events. Exclusion Criteria: 1. Pure ductal carcinoma in situ (DCIS) without an invasive component. 2. Special histological subtypes of invasive carcinoma (e.g., metaplastic carcinoma) with distinct biological behaviors. 3. No original lesion samples were retained before neoadjuvant therapy. 4. Presence of contralateral breast cancer or a history of any other prior malignancy (except for cured non-melanoma skin cancer or carcinoma in situ of the cervix). 5. H\&E or IHC slides with significant technical artifacts (e.g., fading, folds, heavy knife marks, tissue tearing, uneven staining) that preclude reliable image analysis. 6. Low tumor cellularity (e.g., tumor area \< 10% in the scanned field of view). 7. Unavailable or unalignable consecutive tissue sections, preventing spatial registration of H\&E and mIHC images. 8. Lack of essential clinicopathological or follow-up data required for model training or validation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

    RECRUITING

    Hangzhou, Zhejiang, China

  • Cancer Institute and Hospital, Tianjin Medical University, China

    NOT_YET_RECRUITING

    Tianjin, Tianjin Municipality, 300060, China

  • Jilin Cancer Hospital

    NOT_YET_RECRUITING

    Changchun, Jilin, 130000, China

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.